| Case Name | Date Filed | Judge | Drug | Patent No(s). |
|---|---|---|---|---|
| Bausch Health Ireland Ltd. v. Lupin Ltd., 19-9178 (D.N.J.) | Apr. 1, 2019 | Hon. Renee Marie Bumb | Plenvu® (polyethylene glycol 3350 / sodium ascorbate / sodium sulfate / ascorbic acid / sodium chloride / potassium chloride oral solution) |
8,999,313 9,626,969 9,592,252 9,707,297 10,016,504 |
| Lipocine Inc. v. Clarus Therapeutics, Inc., 19-0622 (D. Del.) | Apr. 2, 2019 | Hon. Leonard P. Stark |
Jatenzo® (testosterone undecanoate capsules) Tlando™ (testerone undecanoate capusules) |
9,034,858 9,205,057 9,480,690 9,757,390 6,569,463 6,923,988 |
| Bausch Health Ireland Ltd. v. Lupin Ltd., 19-0626 (D. Del.) | Apr. 3, 2019 | Hon. Colm F. Connolly | Plenvu® (polyethylene glycol 3350 / sodium ascorbate / sodium sulfate / ascorbic acid / sodium chloride / potassium chloride oral solution) |
8,999,313 9,326,969 9,592,252 9,707,297 10,016,504 |
| Ferring Pharms. Inc. v. Hetero USA Inc., 19-0634 (D. Del.) | Apr. 4, 2019 | Hon. Richard G. Andrews | Prepopik® (citric acid / magnesium oxide / sodium picosulfate oral solution) |
8,450,338 8,481,083 |
| Sun Pharm. Indus. Ltd. v. Pfizer, Inc., 19-9330 (D.N.J.) | Apr. 5, 2019 | Hon. Kevin McNulty | Lyrica® CR (pregabalin extended-release tablets) | 9,393,205 |
| Sun Pharm. Indus. Ltd. v. Pfizer, Inc., 19-9335 (D.N.J.) | Apr. 5, 2019 | Hon. Kevin McNulty | Lyrica® CR (pregabalin extended-release tablets) |
8,945,620 9,144,559 10,022,447 |
| Almirall, LLC v. Amneal Pharms. LLC, 19-0658 (D. Del.) | Apr. 9, 2019 | Hon. Leonard P. Stark | Aczone® (dapsone gel) | 9,517,219 |
| Silvergate Pharms., Inc. v. Amneal Pharms. LLC, 19-0678 (D. Del.) | Apr. 11, 2019 | Hon. Leonard P. Stark | Epaned® (enalapril maleate oral solution) |
9,669,008 9,80,8442 10,039,745 10,154,987 |
| Vanda Pharms. Inc. v. Apotex Inc., 19-0685 (D. Del.) | Apr. 12, 2019 | Hon. Colm F. Connolly | Hetlioz® (tasimelteon capsules) | 10,149,829 |
| Celgene Corp. v. Synthon Pharms. Inc., 19-9737 (D.N.J.) | Apr. 12, 2019 | Hon. Esther Salas | Pomalyst® (pomalidomide capsules) |
10,093,647 10,093,648 10,093,649 |
| Allergan Sales, LLC v. Micro Labs Ltd., 19-9759 (D.N.J.) | Apr. 12, 2019 | Hon. Esther Salas | Fetzima® (levomilnacipran HCl extended-release capsules) |
8,481,598 8,864937 RE43879 |
| Celgene Corp. v. Sun Pharma Global FZE, 19-10099 (D.N.J.) | Apr. 16, 2019 | Hon. Susan D. Wigenton | Revlimid® (lenalidomide capsules) |
7,977,357 8,193,219 8,431,598 |
| Par Pharm., Inc. v. Amneal Pharms. Co. GmbH, 19-0712 (D. Del.) | Apr. 18, 2019 | Hon. Colm F. Connolly | Vasostrict® (vasopressin for injection) |
9,744,209 9,750,985 |
| Inspirion Delivery Sciences, LLC v. Teva Pharms. USA, Inc., 19-10464 (D.N.J.) | Apr. 19, 2019 | Hon. Madeline Cox Arleo | MorphaBond® (morphine sulfate extended-release tablets) | 7,955,619 |
| Bausch Health Ireland Ltd. v. Zydus Pharms. (USA), Inc., 19-10645 (D.N.J.) | Apr. 22, 2019 | Hon. Renee Marie Bumb | Glumetza® (metformin HCl extended-release tablets) |
6,488,962 6,723,340 7,780,987 8,323,692 |
| Cipla Ltd. v. AstraZeneca AB, 19-0733 (D. Del.) | Apr. 24, 2019 | Hon. Maryellen Noreika | Nexium® (esomeprazole magnesium delayed-release oral suspension) | 6,428,810 |
| Salix Pharms., Ltd. v. Sun Pharms. Indus., Ltd., 19-0734 (D. Del.) | Apr. 24, 2019 | Hon. Richard G. Andrews | Xifaxan® (rifaximin tablets) |
7,045,620 7,612,199 7,902,206 7,906,542 8,158,644 8,158,781 8,835,452 8,853,231 7,915,275 8,193,196 8,518,949 8,741,904 9,271,968 7,928,115 |
| Osi Pharms., LLC v. Zydus Pharms. (USA) Inc., 19-0741 (D. Del.) | Apr. 25, 2019 | Hon. Colm F. Connolly | Tarceva® (erlotinib HCl tablets) | 6,900,221 |
| Pfizer Inc. v. Aizant Drug Research Solutions Pvt. Ltd., 19-0743 (D. Del.) | Apr. 25, 2019 | Hon. Colm F. Connolly | Ibrance® (palbociclib capsules) |
6,936,612 7,208,489 7,456,168 |
| Pfizer Inc. v. Alembic Pharms., Inc., 19-0745 (D. Del.) | Apr. 25, 2019 | Hon. Colm F. Connolly | Ibrance® (palbociclib capsules) | 6,936,612 |
| Pfizer Inc. v. Apotex Inc., 19-0747 (D. Del.) | Apr. 25, 2019 | Hon. Colm F. Connolly | Ibrance® (palbociclib capsules) |
6,936,612 7,208,489 7,456,168 |
| Pfizer Inc. v. Aurobindo Pharma, Ltd., 19-0748 (D. Del.) | Apr. 25, 2019 | Hon. Colm F. Connolly | Ibrance® (palbociclib capsules) |
6,936,612 7,208,489 7,456,168 |
| Pfizer Inc. v. Cipla USA Inc., 19-0749 (D. Del.) | Apr. 25, 2019 | Hon. Colm F. Connolly | Ibrance® (palbociclib capsules) |
6,936,612 7,208,489 7,456,168 |
| Pfizer Inc. v. Dr. Reddy’s Labs., Inc., 19-0750 (D. Del.) | Apr. 25, 2019 | Hon. Colm F. Connolly | Ibrance® (palbociclib capsules) |
6,936,612 7,208,489 7,456,168 |
| Pfizer Inc. v. Hetero USA, Inc., 19-0751 (D. Del.) | Apr. 25, 2019 | Hon. Colm F. Connolly | Ibrance® (palbociclib capsules) |
6,936,612 7,208,489 7,456,168 |
| Pfizer Inc. v. Mylan Pharms. Inc., 19-0752 (D. Del.) | Apr. 25, 2019 | Hon. Colm F. Connolly | Ibrance® (palbociclib capsules) |
6,936,612 7,208,489 7,456,168 |
| Pfizer Inc. v. Natco Pharma, Inc., 19-0753 (D. Del.) | Apr. 25, 2019 | Hon. Colm F. Connolly | Ibrance® (palbociclib capsules) |
6,936,612 7,208,489 7,456,168 |
| Pfizer Inc. v. Qilu Pharma, Inc., 19-0754 (D. Del.) | Apr. 25, 2019 | Hon. Colm F. Connolly | Ibrance® (palbociclib capsules) |
6,936,612 7,208,489 7,456,168 |
| Pfizer Inc. v. Sun Pharm. Indus., Ltd., 19-0758 (D. Del.) | Apr. 25, 2019 | Hon. Colm F. Connolly | Ibrance® (palbociclib capsules) |
6,936,612 7,208,489 |
| Pfizer Inc. v. Teva Pharms. USA, Inc., 19-0759 (D. Del.) | Apr. 25, 2019 | Hon. Colm F. Connolly | Ibrance® (palbociclib capsules) |
6,936,612 7,208,489 7,456,168 |
| Pfizer Inc. v. Zydus Pharms. (USA) Inc., 19-0760 (D. Del.) | Apr. 25, 2019 | Hon. Colm F. Connolly | Ibrance® (palbociclib capsules) |
6,936,612 7,208,489 7,456,168 |
| Teijin Ltd. v. Alkem Labs. Ltd., 19-0768 (D. Del.) | Apr. 26, 2019 | Hon. Richard G. Andrews | Uloric® (febuxostat tablets) |
7,361,676 8,372,872 9,107,912 |
| Adamis Pharms. Corp. v. Belcher Pharms., LLC, IPR2019-01021 (PTAB) | Apr. 26, 2019 | N/A | Epinephrine for injection | 9,283,197 |
| Pfizer Inc. v. Aizant Drug Research Solutions Pvt. Ltd., 19-11737 (D.N.J.) | Apr. 29, 2019 | Hon. Renee Marie Bumb | Ibrance® (palbociclib capsules) |
6,936,612 7,208,489 7,456,168 |
| Pfizer Inc. v. Dr. Reddy’s Labs., Inc., 19-11742 (D.N.J.) | Apr. 29, 2019 | Hon. Renee Marie Bumb | Ibrance® (palbociclib capsules) |
6,936,612 7,208,489 7,456,168 |
| Pfizer Inc. v. Sun Pharm. Indus., Ltd., 19-11746 (D.N.J.) | Apr. 29, 2019 | Hon. Renee Marie Bumb | Ibrance® (palbociclib capsules) |
6,936,612 7,208,489 |
| Pfizer Inc. v. Zydus Pharms. (USA) Inc., 19-11748 (D.N.J.) | Apr. 29, 2019 | Hon. Renee Marie Bumb | Ibrance® (palbociclib capsules) |
6,936,612 7,208,489 7,456,168 |
| Pfizer Inc. v. Mylan Pharms. Inc., 19-0097 (N.D.W.V.) | Apr. 29, 2019 | Hon. Irene M. Keeley | Ibrance® (palbociclib capsules) |
6,936,612 7,208,489 7,456,168 |
| Pfizer Inc. v. Qilu Pharma, Inc., 19-1846 (E.D. Pa.) | Apr. 29, 2019 | Hon. Gene E.K. Pratter | Ibrance® (palbociclib capsules) |
6,936,612 7,208,489 7,456,168 |
| Arena Pharms., Inc. v. Aurobindo Pharma Ltd., 19-0811 (D. Del.) | May 1, 2019 | Hon. Richard G. Andrews | Belviq® (lorcaserin HCl tablets) |
6,953,787 7,514,422 7,977,329 8,207,158 8,273,734 9,770,455 |
| Bausch Health Ireland Ltd. v. Glenmark Pharms. Ltd., 19-12045 (D.N.J.) | May 1, 2019 | Hon. Renee Marie Bumb | Glumetza® (metformin HCl extended-release tablets) |
6,488,962 6,723,340 7,780,987 8,323,692 |
| Merck Sharp & Dohme Corp. v. Mylan Pharms. Inc., 19-0101 (N.D.W.V.) | May 2, 2019 | Hon. Irene M. Keeley |
Januvia® (sitagliptin phosphate tablets) Janumet® (metformin HCI / stagliptin phosphate tablets) |
7,326,708 8,414,921 |
| Pfizer Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2019-00977 (PTAB) | May 2, 2019 | N/A |
Lantus® Solostar (insulin glargine recombinant for injection) Apidra® Solostar (insulin glulisine recombinant for injection) Toujeo® Max Solostar (insulin glargine recombinant subcutaneous solution) Toujeo® Solostar (insulin glargine recombinant subcutaneous solution) Soliqua® (insulin glargine / lixisenatide subcanteous solution) Admelog® Solostar (insulin lispro for injecction) |
8,603,044 |
| Pfizer Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2019-00978 (PTAB) | May 2, 2019 | N/A |
Lantus® Solostar (insulin glargine recombinant for injection) Apidra® Solostar (insulin glulisine recombinant for injection) Toujeo® Max Solostar (insulin glargine recombinant subcutaneous solution) Toujeo® Solostar (insulin glargine recombinant subcutaneous solution) Soliqua® (insulin glargine / lixisenatide subcanteous solution) Admelog® Solostar (insulin lispro for injecction) |
8,603,044 |
| Pfizer Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2019-00979 (PTAB) | May 2, 2019 | N/A |
Lantus® Solostar (insulin glargine recombinant for injection) Apidra® Solostar (insulin glulisine recombinant for injection) Toujeo® Max Solostar (insulin glargine recombinant subcutaneous solution) Toujeo® Solostar (insulin glargine recombinant subcutaneous solution) Soliqua® (insulin glargine / lixisenatide subcanteous solution) Admelog® Solostar (insulin lispro for injecction) |
8,679,069 |
| Pfizer Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2019-00980 (PTAB) | May 2, 2019 | N/A |
Lantus® Solostar (insulin glargine recombinant for injection) Apidra® Solostar (insulin glulisine recombinant for injection) Toujeo® Max Solostar (insulin glargine recombinant subcutaneous solution) Toujeo® Solostar (insulin glargine recombinant subcutaneous solution) Soliqua® (insulin glargine / lixisenatide subcanteous solution) Admelog® Solostar (insulin lispro for injecction) |
8,992,486 |
| Pfizer Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2019-00981 (PTAB) | May 2, 2019 | N/A |
Lantus® Solostar (insulin glargine recombinant for injection) Apidra® Solostar (insulin glulisine recombinant for injection) Toujeo® Max Solostar (insulin glargine recombinant subcutaneous solution) Toujeo® Solostar (insulin glargine recombinant subcutaneous solution) Soliqua® (insulin glargine / lixisenatide subcanteous solution) Admelog® Solostar (insulin lispro for injecction) |
8,992,486 |
| Pfizer Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2019-00982 (PTAB) | May 2, 2019 | N/A |
Lantus® Solostar (insulin glargine recombinant for injection) Apidra® Solostar (insulin glulisine recombinant for injection) Toujeo® Max Solostar (insulin glargine recombinant subcutaneous solution) Toujeo® Solostar (insulin glargine recombinant subcutaneous solution) Soliqua® (insulin glargine / lixisenatide subcanteous solution) Admelog® Solostar (insulin lispro for injecction) |
8,992,486 |
| Pfizer Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2019-00987 (PTAB) | May 2, 2019 | N/A |
Lantus® Solostar (insulin glargine recombinant for injection) Apidra® Solostar (insulin glulisine recombinant for injection) Toujeo® Max Solostar (insulin glargine recombinant subcutaneous solution) Toujeo® Solostar (insulin glargine recombinant subcutaneous solution) Soliqua® (insulin glargine / lixisenatide subcanteous solution) Admelog® Solostar (insulin lispro for injecction) |
9,604,008 |
| Pfizer Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2019-01022 (PTAB) | May 2, 2019 | N/A |
Lantus® Solostar (insulin glargine recombinant for injection) Apidra® Solostar (insulin glulisine recombinant for injection) Toujeo® Max Solostar (insulin glargine recombinant subcutaneous solution) Toujeo® Solostar (insulin glargine recombinant subcutaneous solution) Soliqua® (insulin glargine / lixisenatide subcanteous solution) Admelog® Solostar (insulin lispro for injecction) |
9,526,844 |
| Pfizer Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2019-01023 (PTAB) | May 2, 2019 | N/A |
Lantus® Solostar (insulin glargine recombinant for injection) Apidra® Solostar (insulin glulisine recombinant for injection) Toujeo® Max Solostar (insulin glargine recombinant subcutaneous solution) Toujeo® Solostar (insulin glargine recombinant subcutaneous solution) Soliqua® (insulin glargine / lixisenatide subcanteous solution) Admelog® Solostar (insulin lispro for injecction) |
9,526,844 |
| Teva Pharms. USA, Inc. v. Corcept Therapeutics, Inc., PGR2019-00048 (PTAB) | May 7, 2019 | N/A | Korlym® (mifepristone tablets) | 10,195,214 |
| Merck Sharp & Dohme Corp. v. Torrent Pharms. Ltd., 19-0872 (D. Del.) | May 9, 2019 | Hon. Richard G. Andrews | Janumet® (metformin HCl / sitagliptin phosphate tablets) | 7,326,708 |
| Collegium Pharm., Inc. v. Teva Pharms. USA Inc., 19-0876 (D. Del.) | May 9, 2019 | Hon. Leonard P. Stark | Xtampza® ER (oxycodone extended-release capsules) | 10,188,644 |
| Bausch Health Ireland Ltd. v. Teva Pharms. USA, Inc., 19-12404 (D.N.J.) | May 9, 2019 | Hon. Renee Marie Bumb | Plenvu® (polyethylene glycol 3350 / sodium ascorbate / sodium sulfate / ascorbic acid / sodium chloride / potassium chloride oral solution) |
8,999,313 9,326,969 9,292,252 9,707,297 10,016,504 |
| Bayer Intellectual Property Gmbh v. Macleods Pharms. Ltd., 19-0880 (D. Del.) | May 10, 2019 | Hon. Timothy B. Dyk | Xarelto® (rivaroxaban tablets) | 9,539,218 |
| Hikma Pharms. USA Inc. v. Micro Labs Ltd., 19-0883 (D. Del.) | May 10, 2019 | Hon. Colm F. Connolly | Mitigare® (colchicine capsules) |
8,927,607 9,399,036 9,555,029 9,675,613 9,789,108 |
| Keryx Biopharms., Inc. v. Lupin Ltd., 19-0884 (D. Del.) | May 10, 2019 | Hon. Leonard P. Stark | Auryxia® (ferric citrate tablets) |
5,753,706 7,767,851 8,093,423 8,299,298 8,338,642 8,609,896 8,754,257 8,754,258 8,846,976 8,901,349 9,050,316 9,387,191 9,757,416 |
| Keryx Biopharms., Inc. v. Watson Labs., Inc., 19-0885 (D. Del.) | May 10, 2019 | Hon. Leonard P. Stark | Auryxia® (ferric citrate tablets) |
7,767,851 8.093.423 8,299,298 8,338,642 8,609,896 8,754,257 8,754,258 8,846,976 8,901,349 9,050,316 9,328,133 9,757,416 |
| Fresenius Medical Care Holdings, Inc. v. Suven Life Sciences Ltd., 19-12479 (D.N.J.) | May 13, 2019 | Hon. Freda L. Wolfson | PhosLo® GelCaps (calcium acetate tablets) |
6,576,665 6,875,445 |
| AstraZeneca Pharms. LP v. Aurobindo Pharma Ltd., 19-12567 (D.N.J.) | May 15, 2019 | Hon. Freda L. Wolfson | Daliresp® (roflumilast tablets) |
8,536,206 8,604,064 8,618,142 |
| Keryx Biopharms., Inc. v. Watson Labs., Inc., 19-0837 (D. Nev.) | May 15, 2019 | Hon. Richard F. Boulware, II | Auryxia® (ferric citrate tablets) |
7,767,851 8,093,423 8,299,298 8,338,642 8,609,896 8,754,257 8,754,258 8,846,976 8,901,349 9,050,316 9,328,133 9,757,416 |
| Ferring Pharms. Inc. v. Lupin Inc., 19-0913 (D. Del.) | May 16, 2019 | Hon. Richard G. Andrews | Clenpiq® (sodium picosulfate / magnesium oxide / anhydrous citric acid oral solution) |
9,827,231 9,669,110 |
| Kaleo, Inc. v. Adamis Pharms. Corp., 19-0917 (D. Del.) | May 16, 2019 | Hon. Richard G. Andrews | Evzio® (naloxone HCl for injection) |
9,022,022 10,143,792 10,238,806 |
| Keryx Biopharms., Inc. v. Par Pharm., Inc., 19-0955 (D. Del.) | May 23, 2019 | Hon. Leonard P. Stark | Auryxia® (ferric citrate tablets) |
8,093,423 9,387,191 |
| CyDex Pharms., Inc. v. Alembic Global Holding SA, 19-0956 (D. Del.) | May 23, 2019 | Hon. Leonard P. Stark | Evomela® (melphalan HCl for injection) |
9,200,088 9,493,582 |
| Valeant Pharms. North America LLC v. KVK-Tech, Inc., 19-12845 (D.N.J.) | May 23, 2019 | Hon. Peter G. Sheridan | Jublia® (efinaconazole topical solution) | 10,105,444 |
| Cubist Pharms. LLC v. Cipla USA, Inc., 19-12920 (D.N.J.) | May 24, 2019 | Hon. Brian R. Martinotti | Cubicin RF® (daptomycin for injection) | 9,138,456 |
| Keryx Biopharms., Inc. v. Par Pharm., Inc., 19-4876 (S.D.N.Y.) | May 24, 2019 | Hon. Edgardo Ramos | Auryxia® (ferric citrate tablets) |
8,093,423 9,387,191 |
| Actelion Pharms. Ltd. v. Natco Pharma Ltd., 19-12984 (D.N.J.) | May 28, 2019 | Hon. Brian R. Martinotti | Tracleer® (bosentan tablets) | 8,309,126 |
| Senju Pharm. Co., Ltd. v. Aurobindo Pharma USA Inc., 19-13348 (D.N.J.) | June 3, 2019 | Hon. Brian R. Martinotti | Prolensa® (bromfenac ophthalmic solution) |
8,129,431 8,669,290 8,754,131 8,871,813 8,927,606 9,144,609 9,517,220 9,561,277 10,085,958 |
| Novartis Pharms. Corp. v. Mylan Pharms. Inc., 19-1042 (D. Del.) | June 5, 2019 | Hon. Richard G. Andrews | Afinitor® (everolimus tablets) |
5,665,772 8,778,962 8,436,010 |
| Novartis Pharms. Corp. v. Mylan Pharms. Inc., 19-0120 (ND.W.V.) | June 6, 2019 | Hon. Irene M. Keeley | Afinitor® (everolimus tablets) |
5,665,772 8,778,962 8,436,010 |
| Silvergate Pharms., Inc. v. Bionpharma Inc., 19-1067 (D. Del.) | June 7, 2019 | Hon. Leonard P. Stark | Epaned® (enalapril maleate oral solution) | 10,154,987 |
| Mylan Pharms. Inc. v. Almirall, LLC, IPR2019-01095 (PTAB) | June 7, 2019 | N/A | Aczone® (dapsone gel) | 9,517,219 |
| Bausch Health Cos. Inc. v. Actavis Labs. FL, Inc., 19-13722 (D.N.J.) | June 13, 2019 | Hon. Stanley R. Chesler | Relistor® (methylnaltrexone bromide tablets) | 10,307,417 |
| Novartis Pharms. Corp. v. Mylan Pharms., Inc., 19-1118 (D. Del.) | June 17, 2019 | Hon. Leonard P. Stark | Gilenya® (fingolimod capsules) | 9,187,405 |
| Vifor (Int’l) AG v. Mylan Labs. Ltd., 19-13955 (D.N.J.) | June 18, 2019 | Hon. Freda L. Wolfson | Injectafer® (ferric carboxymaltose for injection) |
7,612,109 7,754,702 8,895,612 9,376,505 |
| Celgene Corp. v. Apotex Inc., 19-13994 (D.N.J.) | June 19, 2019 | Hon. Susan D. Wigenton | Revlimid® (lenalidomide capsules) |
7,977,357 8,193,219 8,431,598 |
| Astellas US LLC v. Dr. Reddy’s Labs., Ltd., 19-1160 (D. Del.) | June 21, 2019 | Hon. Colm F. Connolly | Lexiscan® (regadenoson for injection) |
8,106,183 RE47,301 8,524,883 |
| Vifor (Int’l) AG v. Mylan Labs. Ltd., 19-0126 (N.D.W.V.) | June 20, 2019 | Hon. Thomas S. Kleeh | Injectafer® (ferric carboxymaltose for injection) |
7,612,109 7,754,702 8,895,612 9,376,505 |
| Astellas US LLC v. Accord Healthcare, Inc., 19-1199 (D. Del.) | June 25, 2019 | Hon. Colm F. Connolly | Lexiscan® (regadenoson for injection) |
8,106,183 RE47,301 8,524,883 |
| Novartis Pharms. Corp. v. Mylan Pharms., Inc., 19-0128 (N.D.W.V.) | June 25, 2019 | Hon. Thomas S. Kleeh | Gilenya® (fingolimod capsules) | 9,187,405 |
| Pfizer Inc. v. Glenmark Pharms. Ltd., 19-1209 (D. Del.) | June 26, 2019 | Hon. Richard G. Andrews | Inlyta® (axitinib tablets) | 8,791,140 |
| Eisai Co. v. Alkem Labs. Ltd., 19-1213 (D. Del.) | June 26, 2019 | Hon. Leonard P. Stark | Banzel® (rufinamide oral suspension) | 6,740,669 |
| Eisai Co. v. Glenmark Pharms. Ltd., 19-1214 (D. Del.) | June 26, 2019 | Hon. Leonard P. Stark | Banzel® (rufinamide oral suspension) | 6,740,669 |
| Piramal Healthcare UK Ltd. v. Sumitomo Dainippon Pharma Co., Ltd., 19-14307 (D.N.J.) | June 26, 2019 | Hon. Stanley R. Chesler | Latuda® (lurasidone HCl tablets) | 8,729,085 |
| Eisai Co. v. Alkem Labs. Ltd., 19-14394 (D.N.J.) | June 27, 2019 | Hon. John Michael Vazquez | Banzel® (rufinamide oral suspension) | 6,740,669 |
| Bayer Intellectual Property Gmbh v. Accord Healthcare, Inc., 19-1238 (D. Del.) | June 28, 2019 | Hon. Timothy Belcher Dyk | Xarelto® (rivaroxaban tablets) | 9,539,218 |
| Bausch Health Ireland Ltd. v. Apotex Inc., 19-14474 (D.N.J.) | June 28, 2019 | Hon. Renee Marie Bumb | Glumetza® (metformin HCl extended-release tablets) |
7,780,987 8,323,692 |
| Bausch Health Ireland Ltd. v. Emcure Pharms. Ltd., 19-14480 (D.N.J.) | June 28, 2019 | Hon. Renee Marie Bumb | Glumetza® (metformin HCl extended-release tablets) |
6,723,340 7,780,987 8,323,692 |
| Bausch Health Ireland Ltd. v. Granules India Ltd., 19-14489 (D.N.J.) | June 28, 2019 | Hon. Renee Marie Bumb | Glumetza® (metformin HCl extended-release tablets) |
6,723,340 7,780,987 8,323,692 |
| Bausch Health Ireland Ltd. v. Glenmark Pharms. Ltd, 19-14502 (D.N.J.) | June 28, 2019 | Hon. Freda L. Wolfson | Bryhali® (halobetasol propionate lotion) | 8,809,307 |
Related Attorneys
Partner
